AVID200

DRUG3 trials

Conditions

Malignant Solid TumorPost ET MFPost PV MFPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera MyelofibrosisPrimary MyelofibrosisScleroderma, Diffuse

Phase 1

Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis

CompletedNCT03831438

Bristol-Myers SquibbScleroderma, Diffuse

Start: 2019-01-01End: 2020-06-20Updated: 2024-11-19

A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies

CompletedNCT03834662

Bristol-Myers SquibbMalignant Solid Tumor

Start: 2019-01-07End: 2020-02-19Updated: 2024-11-19

MPN-RC 118 AVID200 in Myelofibrosis

CompletedNCT03895112

John MascarenhasPost-essential Thrombocythemia Myelofibrosis, Post ET MF, Post-polycythemia Vera Myelofibrosis +2

Start: 2019-02-15End: 2022-05-16Updated: 2023-02-10

Blood2025-07-111 citations

New advances in cancer therapy targeting TGF-β signaling pathways

Molecular Therapy — Oncolytics2023-12-0127 citations

Treatment of Myelofibrosis Patients with the TGF-β 1/3 Inhibitor AVID200 (MPN-RC 118) Induces a Profound Effect on Platelet Production

Blood2021-11-0516 citations

PD-1 inhibition in advanced myeloproliferative neoplasms

Blood Advances2021-09-2837 citations

AVID200, first-in-class TGF-beta 1 and 3 selective and potent inhibitor: Safety and biomarker results of a phase I monotherapy dose-escalation study in patients with advanced solid tumors.

Journal of Clinical Oncology2020-05-2025 citations

P856 AVID200, first-in-class TGF-beta1 and beta3 selective inhibitor: results of a phase 1 monotherapy dose escalation study in solid tumors and evidence of target engagement in patients

Poster presentations2020-04-018 citations

AVID200

Sponsors

Conditions

Phase 1

Related Papers